Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.67% | 20.39% | -19.21% | -41.31% | -43.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.67% | 20.39% | -19.21% | -41.31% | -43.62% |
| Cost of Revenue | 41.40% | -93.78% | -97.98% | -100.37% | -100.68% |
| Gross Profit | 9.28% | 162.16% | 165.41% | 150.65% | 143.39% |
| SG&A Expenses | 92.20% | -6.91% | -17.43% | -33.97% | -5.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.32% | 4.67% | -9.63% | -26.70% | -18.41% |
| Operating Income | -57.95% | -0.32% | 5.92% | 21.02% | 9.38% |
| Income Before Tax | -53.53% | 4.49% | 10.25% | 17.10% | 12.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.53% | 4.49% | 10.25% | 17.10% | 12.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.53% | 4.49% | 10.25% | 17.10% | 12.74% |
| EBIT | -57.95% | -0.32% | 5.92% | 21.02% | 9.38% |
| EBITDA | -58.23% | -0.32% | 5.92% | 21.06% | 9.34% |
| EPS Basic | -52.70% | 4.00% | 10.81% | 17.50% | 12.94% |
| Normalized Basic EPS | -61.54% | -5.88% | 2.86% | 19.51% | 11.36% |
| EPS Diluted | -52.70% | 4.00% | 10.81% | 17.50% | 12.94% |
| Normalized Diluted EPS | -61.54% | -5.88% | 2.86% | 19.51% | 11.36% |
| Average Basic Shares Outstanding | 0.07% | 0.03% | 0.01% | 0.01% | 0.01% |
| Average Diluted Shares Outstanding | 0.07% | 0.03% | 0.01% | 0.01% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |